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Cells, Mediates Chemotaxis and Predicts Poor Prognosis
in Normal Karyotype AML
Marta E. Capala, Edo Vellenga, Jan Jacob Schuringa*
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Netherlands
Abstract
Both normal as well leukemic hematopoietic stem cells critically depend on their microenvironment in the bone marrow for
processes such as self-renewal, survival and differentiation, although the exact pathways that are involved remain poorly
understood. We performed transcriptome analysis on primitive CD34+ acute myeloid leukemia (AML) cells (n = 46), their
more differentiated CD342 leukemic progeny, and normal CD34+ bone marrow cells (n = 31) and focused on differentially
expressed genes involved in adhesion and migration. Thus, Engulfment and Motility protein 1 (ELMO1) was identified
amongst the top 50 most differentially expressed genes. ELMO1 is a crucial link in the signaling cascade that leads to
activation of RAC GTPases and cytoskeleton rearrangements. We confirmed increased ELMO1 expression at the mRNA and
protein level in a panel of AML samples and showed that high ELMO1 expression is an independent negative prognostic
factor in normal karyotype (NK) AML in three large independent patient cohorts. Downmodulation of ELMO1 in human CB
CD34+ cells did not significantly alter expansion, progenitor frequency or differentiation in stromal co-cultures, but did result
in a decreased frequency of stem cells in LTC-IC assays. In BCR-ABL-transduced human CB CD34+ cells depletion of ELMO1
resulted in a mild decrease in proliferation, but replating capacity of progenitors was severely impaired. Downregulation of
ELMO1 in a panel of primary CD34+ AML cells also resulted in reduced long-term growth in stromal co-cultures in two out of
three cases. Pharmacological inhibition of the ELMO1 downstream target RAC resulted in a severely impaired proliferation
and survival of leukemic cells. Finally, ELMO1 depletion caused a marked decrease in SDF1-induced chemotaxis of leukemic
cells. Taken together, these data show that inhibiting the ELMO1-RAC axis might be an alternative way to target leukemic
cells.
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Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease in
which various molecular events lead to a block in differentiation
along the myeloid lineage, resulting in an accumulation of
immature cells termed leukemic blasts, as well as impaired normal
hematopoiesis. The current classification of AML based on
morphological, cytogenetic and molecular abnormalities does
not cover the heterogeneity in response to treatment, especially in
the intermediate risk group constituting the majority (60%) of
AML cases [1,2]. Therefore, new markers that would allow a more
accurate stratification of patients are needed to better guide
treatment options. In recent years, several gene expression
profiling (GEP) studies have been performed in order to identify
leukemia-specific gene expression patterns and select a gene, or
more likely a panel of genes, that could be used to better classify
patients within the existing subgroups [3–8]. However, most of
these studies were performed on the total mononuclear fraction
(MNC) of AML samples, which contains mostly leukemic blasts.
It has been shown that leukemic stem cell (LSC) activity,
similarly to normal hematopoietic stem cell (HSC) activity, is
contained within the CD34+ fraction of AML cells in the vast
majority of cases [9–13]. LSCs are defined as the cells able to
transplant leukemia into immunodeficient recipients. In patients,
LSCs are thought to be responsible for the relapse of disease and
treatment failure [9,14–16]. Therefore, we compared gene
expression profiles of CD34+ AML, their CD342 progeny and
normal bone marrow (NBM) CD34+ cells [17,18]. Here, we
focused specifically on genes that might be involved in adhesion
and/or migration properties and thus were able to identify
Engulfment and Motility protein 1 (ELMO1) amongst the top 50
CD34+ AML-specific genes. ELMO1 is known to be a crucial link
in the signaling cascade leading to the activation of Rac GTPases
[19–21]. We identified ELMO1 as an independent prognostic
marker in the normal karyotype (NK) AML subgroup and showed
that high expression of ELMO1 was associated with poor
prognosis in three independent cohorts of patients. Knockdown
of ELMO1 or inhibition one of its downstream protein RAC
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impaired long-term expansion of leukemic cells on stroma, and
ELMO1 depletion decreased the migration potential of hemato-
poietic cells towards an SDF-1 gradient.
Materials and Methods
Primary cell isolation and culture conditions
Neonatal cord blood (CB) was obtained from healthy full-term
pregnancies after informed consent in accordance with the
Declaration of Helsinki from the obstetrics departments of the
University Medical Centre Groningen (UMCG) and Martini
Hospital Groningen, Groningen, The Netherlands. All protocols
were approved by the Medical Ethical Committee of the UMCG.
After separation of mononuclear cells with lymphocyte separation
medium (PAA Laboratories, Coble, Germany), CD34+ cells were
isolated using a magnetically activated cell sorting (MACS) CD34
progenitor kit (Miltenyi Biotech, Amsterdam, The Netherlands).
For liquid cultures, CD34+ cells were expanded in human
progenitor growth medium (HPGM; Cambrex, Verviers, Belgium)
supplemented with 100 ng/ml stem cell factor (SCF), FLT3
Ligand (Flt3L; both from Amgen, Thousand Oaks, USA) and
thrombopoietin (TPO; Kirin, Tokyo, Japan). For the MS5 co-
culture experiments, cells were grown in Gartner’s medium
consisting of a-modified essential medium (a–MEM; Fisher
Scientific Europe, Emergo, The Netherlands) supplemented with
12.5% heat-inactivated fetal calf serum (Lonza, Leusden, The
Netherlands), 12.5% heat-inactivated horse serum (Invitrogen,
Breda, The Netherlands), 1% penicillin and streptomycin, 2 mM
glutamine (all from PAA Laboratories), 57.2 mM b-mercaptoeth-
anol (Merck Sharp & Dohme BV, Haarlem, The Netherlands) and
1 mM hydrocortisone (Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands). AML blasts from peripheral blood cells or bone
marrow cells from untreated patients with AML were obtained
and studied after informed consent in accordance with the
Declaration of Helsinki, and the protocol was approved by the
Medical Ethical Committee. AML mononuclear cells were
isolated by density gradient centrifugation, and CD34+ cells were
stained using CD34-PE antibody (BD Biosciences, San Jose, CA,
USA) and selected by sorting on a MoFLo (DakoCytomation,
Carpinteria, CA, USA). AML co-cultures were expanded in
Gartner’s medium supplemented with 20 ng/mL interleukin 3
(IL-3; Gist-Brocades, Delft, The Netherlands), granulocyte-colony
stimulating factor (G-CSF; Rhone-Poulenc Rorer, Amstelveen,
The Netherlands) and TPO.
Cell lines and culture conditions
293T embryonic kidney cells (ACC-635 DSMZ, Braunschweig,
Germany) and PG13 packaging cells (ATCC CRL-10686, Wesel,
Germany) were grown in DMEM medium with 200 mM
glutamine (BioWhittaker, Veries, Belgium) supplemented with
10% FSC and 1% penicillin and streptomycin. K562 myelogenous
leukemia cells (ACC-10, DSMZ), TF-1 erythroleukemic cells
(ACC-334, DSMZ) and THP-1 acute monocytic leukemia cells
(ACC-16, DSMZ) were grown in RPMI medium with 200 mM
glutamine (BioWhittaker) supplemented with 10% FCS, and 1%
penicillin and streptomycin, and for TF-1 cells with 5 ng/ml
granulocyte-macrophage colony stimulating factor (GM-CSF;
Genetics Institute, Cambridge, MA, USA). MS-5 murine stromal
cells (ACC-441, DSMZ) were grown in aMEM with 200 mM
glutamine (BioWhittaker) supplemented with 10% FCS and 1%
penicillin and streptomycin.
Immunoblotting
Western blot analysis was performed according to standard
protocols and as described previously [22]. Briefly, 56105 cells
were lysed to prepare whole cell extract by boiling in Laemmli
buffer for 5 min prior to separation on 12.5% SDS gels. After
overnight transfer, membranes were blocked in phosphate-buffer
saline (PBS) with 5% nonfat milk prior to incubating with
antibodies. Binding of antibodies was detected by chemilumines-
cence, according to the manufacturer’s instructions (Roche
Diagnostics, Basel, Switzerland). Antibody against ELMO1
(ab2239) was obtained from Abcam (Abcam, Cambridge, UK)
and was used at a dilution of 1:1000. Antibody against
phosphoPAK (#2601) was obtained from Cell Signaling (Cell
Signaling, Leiden, The Netherlands) and used at a dilution of
1:1000. Antibody against b-actin (#J2207, Santa Cruz Biotech-
nology, CA, USA) was used at a dilution of 1:4000. Secondary
antibodies were purchased from Dako Cytomation (Dako
Cytomation, Glosturp, Denmark) and used at 1:2500 dilutions.
RNA extraction and Real-time PCT analysis
ELMO1 expression was assessed by quantitative real-time PCR
(qRT-PCR) as described previously [23]. Briefly, total RNA was
isolated using an RNeasy kit (Qiagen, Venlo, The Netherlands)
following the manufacturer’s recommendations. After reverse
transcription using M-MuLV reverse transcriptase (Fermentas,
St Leon-Roth, Germany), according to manufacturer’s instruc-
tions, aliquots of cDNA were real-time amplified using iQ SYBR
Green mix (Bio-Rad, CA, USA) on a MyIQ thermocycler (Bio-
Rad). ELMO1 primers (forward primer: CCGGATTGTGCTT-
GAGAACA, reverse primer: CTCACTAGGCAACTCGCCCA)
were obtained from Invitrogen. Expression was quantified using
MyIQ software (Bio-Rad) and RPL27 expression was used to
calculate relative expression levels of investigated genes according
to the standard curve method. RPL27 was not differentially
expressed in our AML versus NBM CD34+ cells (data not shown).
Retro- and lentivirus generation and transduction
Stable PG13 producer cell lines of BCR-ABL retroviral
constructs were generated and used as published previously [24].
Supernatants from the PG13 cells were harvested after 8–12 hours
of incubation in HPGM before the retroviral transduction rounds
and passed through 0.45-mm filters (Sigma-Aldrich). Before the
first transduction round, CD34+ CB cells were pre-stimulated for
48 hours in HPMG supplemented with 100 ng/mL of SCF, Flt3L
and TPO. Three rounds of transduction were performed on
retronectin-coated 24-well plates in the presence of the same
cytokines as for pre-stimulation and 4 mg/mlLpolybrene (Sigma-
Aldrich). With the last round of transduction, lentiviral transduc-
tion with the constructs described below was performed.
Short hairpin RNA (shRNA) sequences targeting ELMO1 were
derived from the literature [25,26] and ligated into pHR’trip
vector using AcsI and SbfI restriction sites. For the control,
scrambled (shSCR) shRNA sequence was used. 293T embryonic
kidney cells were transfected using FuGENE6 (Roche, Almere,
The Netherlands) with 3 mg pCMV D8.91, 0,7 mg VSV-G, and
3 mg of vector constructs (pHR’trip-Scrambled shRNA [shSCR],
or -ELMO1 shRNA [shELMO1]). After 24 hours, medium was
changed to HPGM and after 12 hours, supernatant containing
lentiviral particles was harvested and either stored at 280uC or
used fresh for transduction of target cells. K562, TF-1, THP-1,
isolated CD34+ CB cells that were pre-stimulated for 12 hours, or
BCR-ABL-transduced CD34+ CB cells were subjected to 1 round
of transduction with lentiviral particles in the presence of
prestimulation cytokines and 4 mg/mL polybrene (Sigma) on
ELMO1 as Prognostic Factor in AML
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retronectin-coated 24-well plates (Takara, Tokyo, Japan). After
transduction, transduced green fluorescent protein-positive (GFP-
positive), truncated nerve growth factor receptor-positive (NGFR-
positive) or double-positive cells were sorted on a MoFlo sorter
(Dako Cytomation). AML CD34+ cells were transduced as
described previously [27]. Briefly, transductions were performed
in 3 consecutive rounds of 8 to 12 hours with lentiviral
supernatant supplemented with 10% FCS, IL-3, granulocyte-
colony stimulating factor (G-CSF; Rhone-Poulenc Rorer, Am-
stelveen, The Netherlands) and TPO (20 ng/m each) and
polybrene (4 mg/mL) on a retronectin-coated 24-wells plate. After
washing away the virus supernatant, unsorted cells were used to
initiate co-cultures.
Liquid cultures, long-term cultures on stroma, CAFC and
CFC assay
For liquid cultures, 36105 CD34+ CB cells or BCR-ABL cells
were plated in 1 mL IMDM medium supplemented with 20%
FSC, 1% P/S and 20 gn/mL of SCF and IL-3. 105 CD34+ CB
cells, 56103 BCR-ABL cells and 46104 cells (AML sample 3),
76104 cells (AML sample 1) or 126104 cells (AML sample 2) were
plated onto a T25 flask pre-coated with MS5 stromal cells (ACC-
441, DSMZ) in 5 ml of Gartner’s medium in duplicate. AML
culture medium was supplemented with 20 ng/mL IL-3, G-CSF
and TPO. Co-cultures were kept at 37uC and 5% CO2 and cells
were demi-depopulated weekly for analysis. For the inhibition of
Rac activity, NSC2766 (NSC; Calbiochem, VWR, Amsterdam,
The Netherlands) was added to the co-culture medium to the final
concentration of 20 mM, 40 mM or 100 mM. CFC assays were
performed as previously described [28]. 1000 CD34+ CB or 500
BCR-ABL-transduced cells were plated in 1 mL of CFC assay
medium consisting of MethoCult H4230 (StemCell Technologies,
France), 1% penicillin and streptomycin, 19% IMDM (PAA
Laboratories), IL-3, interleukin-6 (IL-6; Gist-Brocades), G-CSF,
SCF (all 20 ng/mL) and 1 U/mL erythropoietin (EPO; Cilag;
Eprex, Brussels, Belgium) in duplicate directly after transduction
and 104 cells were used at later time points. After 14 days of
culturing colony-forming unit granulocyte-macrophage (CFU-
GM) and burst-forming unit erythroid (BFU-E) were scored. For
CFC replate, colony cells were harvest after 14 days of culture, and
105 cells were plated in 1 ml fresh CFC assay medium in
duplicate. For CAFC assay, CFC assay medium was added to the
co-cultures after 5 weeks. CAFC were counted 2 weeks after the
addition of CFC medium by microscopic evaluation of co-cultures.
Flow cytometry analysis and sorting
All fluorescence-activated cell sorter (FACS) analyses were
performed on a FACScalibur (Becton-Dickinson [BD], Alpen a/d
Rijn, the Netherlands) and data were analyzed using WinList 3D
(Verity Software House, Topsham, USA). Cells were sorted on a
MoFlo sorter. Antibodies: CD34-PE, NGFR-APC, CD14-PE,
CD15-APC, CD71-APC and GPA-PE were obtained from BD.
Viability was assessed using Annexin V APC (IQ Products,
Groningen, The Netherlands) according to the manufacturer’s
recommendations. Briefly, cells were harvested, resuspended in
100 mL calcium buffer containing 5 mL Annexin V, and incubated
for 20 min at 4uC in the dark, washed with 5 mL calcium buffer
and binding of APC-conjugated Annexin V was measured by
FACS.
Migration assay
Migration assays were performed in transwell plates with 8 mm
pore size (Corning Costar, Cambridge, UK) towards the gradient
of SDF-1 (100 ng/mL; R&D Systems, Abingdon, UK). TF-1 or
THP-1 leukemic cell lines were transduced with either shSCR or
shELMO1, sorted and plated in the upper chamber of the
transwell. Migration was allowed for 4 hours, after which the cells
were harvested from the bottom chamber and counted by FACS
using TruCOUNT counting beads (BD).
Statistical analysis and transcriptome datasets used
Statistical analyses were performed with SPSS software (IBM,
Amsterdam, The Netherlands), release 16.0. The association
between the transcript level of ELMO1 and overall survival (OS)
was tested in univariate Cox models. All values are expressed as
means 6 standard deviation (SD). Student’s t test was used for all
other comparisons. All tests were two tailed, and differences were
considered statistically significant at p,0,05.
We made use of various previously published transcriptome
datasets in our studies here. For Figure 1A,B, C and D we used
data generated by ourselves containing AML CD34+ (n = 46) and
NBM CD34+ (n = 31) [18] deposited in GEO under GEO30029).
For Figure 1H we used data of intermediate risk AML samples
(total cohort of 525 patients of which 300 were intermediate risk)
[6,29] deposited in GEO under GSE6891. At page 10 we describe
data in two other NK AML datasets generated by the Bullinger lab
indicating that high ELMO1 expression also predicts poor
prognosis in these datasets and these data were already included
in the Supplemental files of our previous paper [18]. Data for
Figure S1B was derived from the HemaExplorer database (http://
servers.binf.ku.dk/hemaexplorer/) [30]. For Figure S1C we used
data from the Noverhstern lab [31].
Results
ELMO1 expression is increased in AML CD34+ cells and
predicts poor prognosis in normal karyotype AML
patients
Recently, we identified AML CD34+ leukemic stem cell-
enriched transcriptomes by comparing gene expression profiles
of paired AML CD34+ and CD342 samples with those of normal
BM CD34+ cells [17,18]. Thus, 1677 AML CD34+-specific genes
were identified (Figure 1A). Based on Gene Ontology (GO)
analysis for Cellular Component (CC) this list of 1677 genes
could be annotated to several CCs such as plasma membrane
(253), cytosol (136), mitochondrion (116), cytoskeleton (108) and
extracellular space (46) (Figure 1B). Since leukemic stem cells
critically depend on their microenvironment in the bone marrow
for processes such as self-renewal and survival, we focused on
differentially expressed genes involved in adhesion and migration
and an overview of selected GO terms is shown in Figure 1C.
Thus, Engulfment and Motility protein 1 (ELMO1) was identified.
In prior analyses we looked for prognostic significance by
univariate cox regression analyses using the continuous transcript
levels of the top 50 CD34+- specific genes and overall survival (OS)
in a large series of de novo normal karyotype AML [18]. ELMO
was present in this list, and could predict OS in 2 independent
cohorts of patients (cohort 1: n= 163, p = 0.021, hazard ratio
1.782 and cohort 2: n= 218, p = 0.015, hazard ratio 1.657) [18].
ELMO1 is a crucial link in the signaling cascade that leads to
activation of RAC GTPases and cytoskeleton rearrangements and
therefore we decided to study its role in more detail. ELMO1
mRNA was significantly higher expressed in AML CD34+ (n = 46)
as compared to AML CD342 cells (p,0.0001), as well as to NBM
CD34+ cells (n = 31) (p,0.0001) (Figure 1D). Increased expression
of ELMO1 was further confirmed by independent Q-PCRs, which
showed a good correlation with the Illumina BeadArrays data
ELMO1 as Prognostic Factor in AML
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(Figure 1E and Figure S1A). Moreover, elevated mRNA expres-
sion was paralleled by an increase on the protein level in two
representative cases (Figure 1F,G). Increased ELMO1 expression
in AML compared to normal stem/progenitor cells was also
observed in the HemaExplorer dataset [30] (Figure S1B). Finally,
we analyzed the expression of ELMO1 in a third independent
cohort of NK AML patients [6,29], which again indicated that
ELMO1 significantly predicts poor survival (p = 0.0034, Fig-
ure 1H).
ELMO1 downmodulation in human CB CD34+ cells does
not alter expansion, colony formation or differentiation,
but results in a significant decrease in stem cell
frequency
In a recent study by Novershtern et al., gene expression
profiling was performed comparing 38 distinct purified popula-
tions of human hematopoietic cells [31]. Analysis of the data
generated in this study revealed that ELMO1 is significantly more
highly expressed in the most primitive hematopoietic compart-
ment (HSCs) as compared with more differentiated cells (Figure
S1C). Therefore, we set out to investigate the effect of ELMO1
depletion in CD34+ population of CB cells, enriched for
hematopoietic stem and progenitor cells (HSPCs). In order to
downregulate ELMO1 expression, lentiviral vectors containing
ELMO1-targeting shRNA sequence were generated (shELMO1).
The efficiency of downregulation was first tested in the K562 cell
line, where transduction with shELMO1 significantly decreased
ELMO1 expression both at the mRNA as well as protein level
(Figure 2A). Subsequently, CB CD34+ cells were transduced with
control (shSCR), or shELMO1-containing vectors, with transduc-
tion efficiencies of 59% for shSCR and 46% for shELMO1
(Figure 2B). Transduced cells were then sorted and plated either in
liquid culture, or in a co-culture on stromal MS5 cells. The growth
of CB CD34+ in liquid culture was followed for 28 days and within
that time no significant differences were observed between the
proliferation of ELMO1-depleted and control cells (Figure 2C). In
contrast, the expansion of shELMO1-transduced cells during the
5-week co-culture on stroma was slightly lower than of the control
cells (Figure 2D, E). We assessed cell differentiation along the
myeloid lineage during the co-culture and saw that it was not
affected by ELMO1 downregulation (Figure S2). Also the
progenitor frequency and their self-renewal potential were not
changed upon ELMO1 depletion. Of note, CFC cells from
shELMO1-transduced group initiated slightly more colonies upon
replate than the control, although this did not reach significance
(Figure 2F). Finally, the LTC-IC frequency was assessed at the end
of co-culture. In the shELMO1-transduced group significantly
fewer colonies were observed (p = 0.042) indicative of the reduced
stem cell frequency (Figure 2G). Overall, these data indicate that
ELMO1 depletion did not significantly affect CB CD34+
proliferation in liquid culture and co-culture, myeloid differenti-
ation or progenitor cell frequencies, but did cause a reduction of
the most primitive stem cells.
Depletion of ELMO1 results in a slight proliferative
disadvantage and reduced replating capacity of BCR-
ABL-transformed human CB CD34+
Several studies have shown that RAC GTPases play an essential
role in leukemic transformation mediated by BCR-ABL oncopro-
tein [32–37]. Since ELMO1 is involved in the activation of RAC
proteins by the Dock180 family of GEFs, we hypothesized that
depletion of ELMO1 would have a profound effect on the
expansion of BCR-ABL-transformed cells. We performed a double
transduction of CD34+ CB cells with BCR-ABL-containing
retroviral vectors, together with shSCR or shELMO1 shRNA-
containing lentiviral vectors. Double-transduced cells were then
sorted (Figure 3A) and plated either in liquid culture or in a co-
culture on MS5 stromal cells. Somewhat contrary to our
expectations, proliferation of BCR-ABL cells was not markedly
affected by ELMO1 downregulation during the 34 days of liquid
culture (Figure 3B). Moreover, ELMO1-depleted BCR-ABL cells
initially showed an increased proliferation in MS5 co-culture, but
upon replating shELMO1-transduced cells did expand significant-
ly less than the control suggesting that self-renewal properties were
affected (Figure 3C, D). No marked differences were observed in
the differentiation potential (data not shown). In the colony
forming assay, shELMO1-transduced cells initiated the same
number of colonies at week 1 of the co-culture, however at week 2
the number of colonies arising from shELMO1-transduced cells
was lower that the control (Figure 3E). Moreover, significantly
fewer secondary colonies were observed upon ELMO1 downreg-
ulation, again suggesting that self-renewal properties might be
affected (Figure 3E). Taken together, these data indicate that
ELMO1 depletion does not markedly affect BCR-ABL-transduced
CB CD34+ cell proliferation in liquid culture and co-culture, but it
decreases replating capacity of progenitor cells.
Effects of ELMO1 depletion on long-term expansion of
primary AML CD34+ cells on MS5 stroma
Next, we investigated the effect of ELMO1 downregulation in a
panel of AML samples that showed high ELMO1 expression levels
in the microarray profiling [18]. The following samples were used:
2003 022 (AML1), 2003 119 (AML2) and 2003 160 (AML3). The
sample characteristics such as FAB classification, cytogenetic
characteristics, risk group according to HOVON/SAKK protocols
and FLT3/NPM mutation status are provided in Table 1. In order
to downmodulate ELMO1, CD34+ cells were sorted from the AML
mononuclear fraction and transduced with shSCR- or shELMO1-
containing lentiviral vectors. Directly after transduction cells were
plated on MS5 stroma and their expansion and GFP expression
were followed during the co-culture. Transduction efficiencies
obtained with shRNA constructs were variable, ranging from 16%
in AML3 to 40% in AML1 and above 60% in AML2. AML3
ceased to expand beyond day 26 and within that time no significant
differences in proliferation between shSCR- and shELMO1-
transduced cells were observed. However, AML1 and AML2 could
expand for as long as 41 days and in those cultures ELMO1-
depleted cells grew markedly less than the control cells (Figure 4).
Figure 1. ELMO1 expression is increased in AML CD34+ cells and predicts poor prognosis in normal karyotype AML patients. (A)
VENN diagram displaying the overlap in AML CD34+ specific and AML CD342 specific transcriptomes compared to NBM CD34+ cells [17,18]. (B) 1677
AML CD34+-specific genes were subjected to Gene Ontology (GO) analysis for Cellular Component (CC) of which several CCs are shown. (C) 1677 AML
CD34+-specific genes were subjected to GO analysis for terms associated with adhesion and migration. (D) ELMO1 mRNA was significantly higher
expressed in AML CD34+ (n = 46) as compared to AML CD342 cells (p,0.0001), as well as to NBM CD34+ cells (n = 31) (p,0.0001). (E) Increased
expression of ELMO1 was further confirmed by independent Q-PCRs in a panel of 11 AML and 6 NBM samples. (F, G) The increase in ELMO1 mRNA
was paralleled by increased protein levels in two representative cases. (H) High expression of ELMO1 predicts poor survival in a cohort of NK AML
patients (based on [6,29]) (p = 0.0034).
doi:10.1371/journal.pone.0111568.g001
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Figure 2. ELMO1 downmodulation in human CB CD34+ cells does not alter growth, colony formation or differentiation, but
significantly decreases stem cell frequency. (A) K562 cells were transduced with control scrambled shRNA vector (shSCR) or with ELMO1-
targeting shRNA vectors (shELMO1), sorted and used for RNA extraction. Quantitative PCR was performed to measure ELMO1 expression in
transduced cells. ELMO1 mRNA levels were normalized against RPL27 mRNA expression. Alternatively, cells were used for Western blot analysis to
determine ELMO1 protein levels. (B) FACS plots showing transduction efficiencies of cord blood (CB) CD34+ stem/progenitor cells transduced with
shSCR or shELMO1. (C) 36105 transduced and sorted cells per group were plated in liquid culture and followed for thirty days. Cumulative cell count
is showed representative of 3 independent experiments. (D) 105 transduced and sorted cells per group were plated on MS5 stromal cells and kept in
the co-culture for 5 weeks; cultures were demi-depopulated weekly for analysis. Weekly cumulative cell growth is shown for a representative
experiment of 3 independent experiments and the average of those 3 experiments is shown in (E). (F) Suspension cells from MS5 co-cultures as
described in panel D were analyzed for progenitor frequency by CFC assay. 104 cells from each co-culture were plated in a CFC assay in
methylcellulose in duplicate, and colonies were evaluated 2 weeks after plating. CFC cells were then harvested and 105 cells were re-plated to form
secondary CFCs. CFU-GM and BFU-E numbers are shown from a representative of 3 independent experiments; error bars indicate standard deviation.
(G) LTC-IC frequencies were determined in bulk on MS5 stromal cells. After 5 weeks of co-culture methylcellulose was added to and colonies were
scored two weeks later. CFU -GM, colony-forming unit-granulocyte-macrophage; BFU-E, burst forming unit-erythroid. * P,0.05, ** P,0.01, *** P,
0.001.
doi:10.1371/journal.pone.0111568.g002
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Global inhibition of RAC activity severely impairs
proliferation and survival of leukemic cells while ELMO1
depletion affects mostly cell migration
Subsequently, we investigated whether global inhibition of RAC
activity, as a downstream target of ELMO1, would have an effect
on the expansion of BCR-ABL-expressing leukemic cells. To this
end, we used either BCR-ABL-transduced CD34+ CB cells, or
primary blast crisis chronic myeloid leukemia (BC CML) cells.
After plating on stroma, cells were allowed to expand and form
cobblestones, after which the RAC inhibitor NSC23766 (NSC)
was added to the co-cultures in concentrations of 20 mM to
100 mM. In BCR-ABL CB cells, inhibition of RAC activity caused
a marked decrease in cell proliferation, apparent as early as 4 days
after the addition of NSC. By day 9, cultures treated with 20 mM
and 40 mM of NSC ceased to expand, while cells treated with
Figure 3. BCR-ABL-transformed human CB CD34+ show proliferative disadvantage and markedly reduced replating capacity upon
ELMO1 depletion. (A) CB CD34+ stem/progenitor cells were double-transduced with BCR-ABL and either control scrambled shRNA vector (shSCR)
or with ELMO1-targeting shRNA vector (shELMO1). FACS plots of transduction efficiency are shown. (B) 36105 double-transduced cells per group
were plated in liquid culture and followed for 35 day. Cumulative cell count is shown representative of 3 independent experiments. (C) 56103
double-transduced cells were sorted per group and plated on MS5 stromal cells; cultures were demi-depopulated on indicated days for analysis and
replated when stroma showed signs of detaching. Cumulative cell growth is shown for a representative experiment of 3 independent experiments
and the average of those 3 experiments is shown in (D). (E) Suspension cells from MS5 co-cultures as described in panel B were analyzed for
progenitor frequency by CFC assay. 103 freshly transduced cells or 104 cells from each co-culture were plated in a CFC assay in methylcellulose in
duplicate, and colonies were evaluated 2 weeks after plating. CFC cells were harvested and 105 cells were replated to assess secondary CFC
formation. Total CFC numbers are shown from a representative of 3 independent experiments; error bars indicate standard deviation. * P,0.05, ** P,
0.01, *** P,0.001.
doi:10.1371/journal.pone.0111568.g003
Table 1. Summary of clinical parameters of AML patients used in this study.
2003 022 2003 119 2003 160
FAB classification M5 M0 M1
Cytogenetic characteristics NK NK complex karyotype
Risk group intermediate poor poor
FLT3/NPM1 ITD/NPMc+ ITD/wt wt/wt
Abbreviations: FLT3, fms-related tyrosine kinase 3; ITD, internal tandem duplication; NK, normal karyotype; NPM1, nucleophosmin 1; NPMc+, cytoplasmic dislocalization
of NPM1; wt, wild type.
doi:10.1371/journal.pone.0111568.t001
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100 mM of inhibitor were depleted from the co-culture (Fig-
ure 5A). Analysis of phosphorylated PAK as a readout for RAC
activity revealed that 40 mM of NSC23766 was sufficient to almost
completely abolish RAC activity in the treated cells (Figure S3A).
NSC-treated co-cultures showed an increased level of apoptotic
cells, and the cells did not recover even after discontinuation of the
treatment (Figure 5C and Figure S3B). Similarly, primary BC
CML cells were highly sensitive to RAC inhibition. Co-cultures
treated with the highest concentration of NSC did not survive past
week 2, while cells treated with 20 mM or 40 mM of the inhibitor
stopped expanding at were lost from the co-culture at week 3
(Figure 5B). The data are directly in line with our previously
published data on the effects of the RAC inhibitor NSC on
primary AML cells, where we also observed a strong reduction in
long-term expansion on MS5 stromal cocultures [22].
Since global inhibition of RAC activity resulted in a much more
severe phenotype than downregulation of ELMO1, we hypothe-
sized that the activation via ELMO1-Dock180 pathway may be
important for only some functions of RAC proteins. RAC
GTPases have a well-described role in regulating migration and
chemotaxis [38]; therefore we investigated the affected of ELMO1
depletion on the migratory potential of leukemic cells. To this end
we transduced leukemic cell lines TF-1 and THP-1 with either
shSCR- or shELMO1-containing lentiviral constructs. Depletion
of ELMO1 resulted in an approximately 20% decrease of
phospho-PAK activity and a slight proliferative disadvantage
(Figure S4A, S4B). However, when we performed a transwell assay
on either shSCR- or shELMO1-transduced leukemic cell lines we
observed a marked decrease in the percentage of cells migrating
towards the SDF-1 gradient upon ELMO1 downmodulation,
indicative of a reduced chemotaxis (Figure 5D). Interestingly,
treatment with RAC inhibitor resulted in a very pronounced
apoptotic response in those cell lines, with virtually all cells dead
within 3 days of treatment with 100 mM of NSC (Figure S4C,
S4D). Therefore, while abolishing RAC activity was detrimental to
the survival and proliferation of leukemic cells, inhibiting ELMO1-
Dock180 activation pathway seemed to affect mostly their
migratory potential.
Discussion
The current study shows that ELMO1 is more highly expressed
in AML CD34+ cells as compared with NBM CD34+ cells, and
that this high expression has a prognostic significance in the NK
subset of AML patients. Depletion of ELMO1 modestly impaired
expansion in the long-term cultures of oncogene-transduced or
primary leukemic CD34+ cells, while chemotaxis towards an SDF-
1 gradient was significantly reduced.
Analysis of the data generated in the study by Novershtern et al.
revealed that ELMO1 was significantly higher expressed in the
most primitive hematopoietic compartment (HSCs) as compared
with the more differentiated cells [31]. Importantly, in a recent
proteome analysis of the plasma membrane fractions of CB
CD34+ cells, we have found ELMO1 to be specifically associated
with the plasma membrane of CD34+/CD382 HSCs (data not
shown). Taken together, these results identified ELMO1 as a
protein most abundant in the primitive compartment of the
hematopoietic system and suggested that ELMO1 might contrib-
ute to the biology of HSCs. Although downregulation of ELMO1
in CB CD34+ cells did not significantly affect proliferation,
differentiation or progenitor cell frequencies, depletion of ELMO1
did result in a significant decrease of stem cell frequencies as
determined by LTC-IC assay. Considering that increased
expression of ELMO1 was predominantly observed within the
most primitive stem and progenitor cells it is conceivable that
those cells are most affected by downregulation of ELMO1.
We identified ELMO1 to be an AML34+-specific gene in a
recent transcriptome analysis of paired AML CD34+ and CD342
samples, and BM CD34+ cells [17,18]. Although to date there is
no data available on the involvement of ELMO1 in the
hematopoietic malignancies, RAC proteins have been identified
as crucial factors in the BCR-ABL- and MLL-AF9-induced
leukemic transformation [32–37]. This led us to hypothesize that
the increased expression of ELMO1 that we observed in leukemic
cells may act by increasing RAC activity in these cells. ELMO1
downregulation in BCR-ABL-transduced CB CD34+ cells or in
primary AML CD34+ cells initially did not strongly affect their
long-term growth in stromal co-cultures, but upon serial replating
of MS5 cocultures or upon serial replating of CFCs a significant
reduction was observed. In two out of three AML cases a
significant reduction in long-term growth on MS5 assays was also
observed. Nevertheless, the effect of global RAC inhibition in
BCR-ABL-expressing cells was far more pronounced than that of
ELMO1 downregulation, both on the RAC activity levels and the
cell proliferation and survival. These data are directly in line with
our previously published data in primary AML cells, where we
also observed a strong reduction in long-term expansion on MS5
stromal cocultures [22]. One possible explanation for differences
Figure 4. ELMO1 depletion in primary AML CD34+ cells impairs long-term expansion on stroma. AML CD34+ cells were transduced with
control scrambled shRNA vector (shSCR) or with ELMO1-targeting shRNA vector (shELMO1). After washing away the virus all the cells were plated on
MS5 stroma; cultures were demi-depopulated on indicated days for analysis. Cumulative cell growth is shown for each AML sample studied.
doi:10.1371/journal.pone.0111568.g004
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in sensitivity towards ELMO or RAC knockdown might be that
the residual ELMO1 expression in the transduced cells was still
sufficient to maintain RAC activity and function. Also, it is
plausible that redundancy exists between other members of the
ELMO family that would compensate for ELMO1 loss, or
alternatively other pathways might have become dominant in
activating RAC upon ELMO1 depletion. Further studies are
required to resolve these issues.
Previous studies have shown that increased expression of
ELMO1 was responsible for the malignant behavior of ovarian
and breast cancer, as well as glioma cells [25,39–41]. In those
cases, ELMO1 played a role in conferring the migratory and
invasive properties of the malignant cells. Accordingly, when we
assessed migratory potential of leukemic cell lines, we saw that it
was reduced upon ELMO1 downmodulation. It is therefore
possible that an increased expression of ELMO1 in LSCs confers
migratory properties that contribute to the malignant phenotype
and worse overall survival of AML patients.
Overall, we have shown that ELMO1 is more highly expressed
in primitive leukemic cells and that it predicts prognosis in NK
AML patients. Further studies using in vivo leukemia models are
necessary to assess whether ELMO1 depletion could affect LSC
homing and long-term engraftment, and ultimately whether
targeting ELMO1 might have therapeutic benefit in the treatment
of leukemia patients.
Supporting Information
Figure S1 (A) Relative mRNA expression of ELMO1 was
analyzed by Q-PCR in a panel of 11 AML samples and the
correlation with Illumina BeadsArray expression data was
assessed. Calculated r2= 0.6. (B) Relative mRNA expression of
ELMO1 (derived from HemaExplorer) was analyzed across
different AML subtypes and compared to NBM populations.
Number of samples per group: AML1-ETO n=39; APL n= 37;
inv16/t16 n= 28; t(11q23) n= 38; HSC_BM n=7; HPC_BM
n=4. (C) Comparison of mRNA expression of ELMO1 in various
human hematopoietic populations analyzed in the Novershtern
dataset.
(TIF)
Figure S2 CD34+ CB cells were transduced with either
control shSCR or shELMO1 constructs, and 105 trans-
Figure 5. Global inhibition of RAC activity severely impairs proliferation and survival of leukemic cells while ELMO1 depletion
strongly affects migration. (A) CB CD34+ cells were transduced with BCR-ABL-expressing vector, sorted and plated on MS5 stroma. Cells were
allowed to proliferate for 5 days after which RAC inhibitor was added to the following concentrations: 20 mM, 40 mM or 100 mM. Co-cultures were
demi-depopulated on indicated days for analysis. Cumulative cell count is shown representative of 3 independent experiments. (B) CD34+ cells were
sorted from BC CML patient sample and plated on MS5 stroma. Cells were allowed to proliferate for 5 days after which RAC inhibitor was added to
the following concentrations: 20 mM, 40 mM or 100 mM. Co-cultures were demi-depopulated on indicated days for analysis. Cumulative cell count is
shown representative of 3 independent experiments. (C) BCR-ABL transduced cells as described in (A) were treated with 50 mM NSC for 3 days after
which suspension cells were harvested and stained with Annexin V to assess apoptosis. (D) TF-1 and THP-1 cells were transduced with control
scrambled shRNA vector (shSCR) or with ELMO1-targeting shRNA vector (shELMO1) and migration was evaluated in a transwell assay. The percentage
of migrating cells relative to control is shown as an average of 3 independent experiments.
doi:10.1371/journal.pone.0111568.g005
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duced and sorted cells per group were plated on MS5
stromal cells and kept in the co-culture for 5 weeks.
Cultures were demi-depopulated weekly and suspension cells were
analyzed for differentiation along myeloid lineages. Percentage of
CD14/CD15-double negative, CD14-positive and CD15-positive
cells are shown.
(TIF)
Figure S3 (A) CB CD34+ cells were transduced with BCR-ABL-
expressing vector, sorted and plated on MS5 stroma. Cells were
allowed to proliferate for 5 days after which RAC inhibitor NSC
was added to the following concentrations: 20 mM, 40 mM or
100 mM. After 3 days of treatment suspension cells were collected
and phospho-PAK levels were assessed by Western blot.
Quantification of phospho-PAK levels relative to control is
indicated above each lane. (B) BCR-ABL-expressing cells as 3
described in (A) were treated with 50 mM NSC and co-cultures
were demi-depopulated on indicated days for analysis. After 20
days NSC was washed away from the culture and treated cells
were culture for additional 13 days after which all the cells were
harvested for analysis. Cell counts are shown representative of 3
independent experiments.
(TIF)
Figure S4 (A) THP-1 cells were transduced with either control
shSCR or shELMO1 vector and sorted. After 5 days of culture
expression of phospo-PAK in transduced cells was analyzed by
Western blot. Quantification of phospho-PAK levels relative to
control is indicated above each lane. (B) shSCR- or shELMO1-
transduced THP-1 cells were cultured for 9 days and cells were
counted on the indicated time points. Cumulative cell count is
shown representative of 3 independent experiments. (C) THP-1
cells were treated with either 50 mM or 100 mM NSC for 3 days
and then stained with Annexin V to assess apoptosis. FACS plots
representative of 3 independent experiments are shown and
quantification of Annexin V (+) cells is shown in (D).
(TIF)
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